241 related articles for article (PubMed ID: 22954583)
1. Minimal disease activity in Gaucher disease: criteria for definition.
Di Rocco M; Andria G; Bembi B; Carubbi F; Giona F; Giuffrida G; Linari S; Sibilio M; Spina V; Cappellini MD
Mol Genet Metab; 2012 Nov; 107(3):521-5. PubMed ID: 22954583
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
5. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
6. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
7. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy for Gaucher disease in Australia.
Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
[TBL] [Abstract][Full Text] [Related]
10. Enzyme Replacement Therapy in a Gaucher Family.
Erdem N; Buran T; Berber I; Aydogdu I
J Natl Med Assoc; 2018 Aug; 110(4):330-333. PubMed ID: 30126557
[TBL] [Abstract][Full Text] [Related]
11. Gaucher disease.
Mignot C; Gelot A; De Villemeur TB
Handb Clin Neurol; 2013; 113():1709-15. PubMed ID: 23622393
[TBL] [Abstract][Full Text] [Related]
12. Gaucher disease: a lysosomal neurodegenerative disorder.
Huang WJ; Zhang X; Chen WW
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(7):1219-26. PubMed ID: 25912581
[TBL] [Abstract][Full Text] [Related]
13. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
[TBL] [Abstract][Full Text] [Related]
15. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
16. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
[TBL] [Abstract][Full Text] [Related]
17. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
18. [French results of enzyme replacement therapy in Gaucher's disease].
Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
[TBL] [Abstract][Full Text] [Related]
19. Taliglucerase alfa for the treatment of Gaucher's disease.
Haddley K
Drugs Today (Barc); 2012 Aug; 48(8):525-32. PubMed ID: 22916340
[TBL] [Abstract][Full Text] [Related]
20. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
Nagral A; Mewawalla P; Jagadeesh S; Kabra M; Phadke SR; Verma IC; Puri RD; Gupta N; Kishnani PS; Mistry PK
Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]